seropositive for Toxoplasma gondii

PreclinicalBiologic

UUniversity Hospital, Strasbourg, France

seropositive for Toxoplasma gondii is one of 4 biologic programs targeting Toxoplasmosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ToxoplasmosisActive, not recruiting

ToxoplasmosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Toxoplasmosis

#DrugCompanyPhaseTrials

Daraprim

FFondazione Matilde Tettamanti Menotti De Marchi Onlus

Approved

—2

Trimethoprim-Sulfamethoxazole

Astellas

Phase 3

1 3

Wellcovorin

EEastern Cooperative Oncology Group

Phase 1

—4

seropositive for Toxoplasma gondii

UUniversity Hospital, Strasbourg, France

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Toxoplasmosis1 trial

Determination of Genetic Susceptibility in Severe Recurrences of Ocular Toxoplasmosis

Terminated·UUniversity Hospital, Strasbourg, France·N/A·NCT02863588·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for seropositive for Toxoplasma gondii. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — seropositive for Toxoplasma gondii compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for seropositive for Toxoplasma gondii. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Strasbourg, France company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Strasbourg, France

seropositive for Toxoplasma gondii

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Toxoplasmosis1 trial

References

Drug Info

Quick Facts

Related News